Indian scientists develop a new vaccine to control classical swine fever

NEW DELHI: Indian scientists from ICAR's Indian (IVRI), Izatnagar in have developed a cell culture (CSF) that will help produce a cost-effective alternative to vaccines currently used to prevent deadly fever in pigs that contribute to 10% of the total from the country. meat production

The locally developed vaccine will also help save rabbits, since the currently used vaccine (lapped CSF vaccine) is produced by sacrificing large numbers of rabbits. In addition, the new vaccine provides immunity for two years compared to the protection of 3 to 6 months under currently used vaccines.

CSF is one of the most lethal diseases of pigs, which causes high mortality with an annual loss of more than 400 crore crore. Although India has been able to prevent the disease to some extent, classical swine fever is considered one of the reasons for causing the decline in pig population in the country in 2019 compared to the 2012 census.

On Monday, the secretary of the department of livestock and milk production, Atul Chaturvedi, said the new vaccine will be part of the government's 'Single Health Initiative' and will generate huge savings. It will reduce the spread of the virus in the animal stage so that it does not pass to the human population.

He said that the country's total requirements are 22 million doses per year and that the lapinized vaccine produces only 1.2 million doses per year, since only 50 doses are produced from a single rabbit spleen.

The officials of the Ministry of Agriculture said that due to the high title of the vaccine virus, this vaccine would be the most economical CSF vaccine, with a cost of less than Rs 2 per dose compared to Rs 15-25 per dose of lapinized vaccine and CS 30 per dose (approx) for an imported Korean vaccine that is currently being used in the country.

Trilochan Mohapatra, general director of the Indian Council for Agricultural Research (ICAR), said there is a high demand for transfer of this new vaccine technology from several state governments and private manufacturers and that the vaccine has enormous export potential, especially Nepal.

The vaccine virus has a very high titer and thousands of doses can be produced very easily in cell culture and the country's requirements can easily be met with this new vaccine, said RK Singh, director of IVRI, adding that the vaccine It is ready for commercial production.

The ministry said the vaccine is safe, potent, does not revert to virulence and provides protective immunity from day 14 of vaccination until the 24 months studied so far. The vaccine has been tested in about 500 pigs in multiple locations.